Heart Failure
Conditions
Keywords
heart failure, nutrition therapy, symptoms, quality of life, lycopene, omega-3 fatty acids
Brief summary
The purpose of is to test the effects of a 6-month nutrition intervention of dietary sodium reduction combined with supplementation of lycopene and omega-3 fatty acids on heart failure symptoms, health-related quality of life, and time to heart failure rehospitalization or all-cause death.
Detailed description
For a majority of patients with advanced heart failure, medical treatment is only partially effective in relieving heart failure symptoms. Therefore, it is recommended that palliative care be initiated soon after diagnosis. There is a need for complementary, nonpharmacologic interventions that could be easily implemented by health care providers to provide palliative care. Three major pathologic pathways underlying heart failure symptoms have been identified: fluid overload, inflammation, and oxidative stress. Prior research has demonstrated that three nutrients-sodium, omega-3 fatty acids, and lycopene-can alter these pathologic pathways. Clinical trials to date have only tested each nutrient individually. There is strong theoretical rationale that a combined intervention targeting all three nutrients would have substantial benefit in relieving symptoms in advanced heart failure. Therefore, the purposes of this study are to test the effects of a 6-month nutrition intervention of dietary sodium reduction combined with supplementation of lycopene and omega-3 fatty acids on heart failure symptoms, health-related quality of life, and time to heart failure rehospitalization or all-cause death. The aims of this placebo controlled study are 1) to determine the effects of a 6-month nutrition intervention on symptom burden (edema, shortness of air, and fatigue) and health related quality of life at 3 and 6 months, and time to heart failure rehospitalization or all-cause death over 12 months from baseline; 2) compare dietary sodium intake, inflammation, and markers of oxidative stress between the nutrition intervention group and a placebo group at 3 and 6 months; and 3) compare body weight, serum lycopene, and erythrocyte omega-3 index between the nutrition intervention group and a placebo group at 3 and 6 months. A total of 150 patients with advanced heart failure will be randomized to either the nutrition intervention or placebo group (75 per group). The nutrition intervention group will receive a theory based education and skill building intervention designed to decrease dietary sodium intake to \ 2 g per day. A research nurse will make 4 home visits and one follow-up telephone call over 6 months to provide the education-skill building intervention. The intervention group will take 3 omega-3 fatty acid capsules (350 mg eicosapentaenoic acid and 50 mg docosahexaenoic acid) and consume tomato juice or other tomato-based products containing 20-25 mg of lycopene daily for six months. The placebo group will receive the same number of visits and phone calls but only general nutrition information will be provided. They will take 3 placebo capsules containing rice oil (500 mg/capsule) and consume their choice of fruit juices that do not contain lycopene daily for six months. Data will be collected in person at baseline, 3 months, and 6 months by a research assistant blinded to the group assignment. Patients will be followed for an additional 6 months by telephone to collect longer term data on symptom burden and quality of life as well as heart failure hospitalization and all-cause mortality at 9 and 12 months.
Interventions
BEHAVIORALSodium reduction
Teaching and skill building to reduce dietary sodium
DIETARY_SUPPLEMENTomega 3 and lycopene supplements
omega-3 fatty acid supplements and juices containing lycopene
DIETARY_SUPPLEMENTrice bran oil capsules
placebo capsules
BEHAVIORALGeneric dietary feedback from
Provided a summary of the 3 day dietary recalls at baseline, 3 months, and 6 months
Sponsors
Ohio State University
Terry Lennie
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* chronic heart failure with either preserved or non-preserved ejection fraction * for chronic heart failure, have undergone evaluation of heart failure and optimization of medical therapy, for patients discharged from hospital for acute/newly diagnosed heart failure, have undergone evaluation of heart failure and optimization of medical therapy for at least 1 month post discharge * New York Heart Association functional classification of II, III or IV * have not been referred for heart transplantation * able to read and speak English * no cognitive impairment that precludes giving informed consent or ability to follow protocol instruction.
Exclusion criteria
* BMI \< 17 kg/m2 or \> 46 kg/m2 * co-existing illness documented in the medical record known to be associated with systemic inflammation decreased appetite or absorption, fatigue, edema, or weight loss * currently taking dietary supplements that contain lycopene or omega-3 fatty acids * allergy to rice bran oil
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Event-Free Survival | 12 months | Combined endpoint of cardiac-related hospitalization and all cause mortality |
| Symptom burden | baseline, 3, 6, 9, and 12 months | combined score of symptom severity, frequency, and distress for common symptoms of heart failure |
| Quality of life | baseline, 3, 6, 9, 12 months | heart failure related quality of life |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Lycopene | baseline, 3, 6, 9, 12 months | Plasma lycopene will be measured as a marker intervention effectiveness |
| omega-3 index | baseline, 3, 6, 9, 12 months | the ratio of EPA plus DHA as a percentage of total fatty acids in the cell membrane of erythrocytes |
| Sodium intake | baseline, 3, 6, 9, 12 months | Three 24-hour diet recall interviews at each timepoint will be used estimate sodium intake and to identify high sodium foods and eating patterns for the sodium reduction component of the intervention. |
| oxidative stress | baseline, 3, 6, 9, 12 months | serum levels of malondialdehyde and 8-iso-PGF2a isoprostane will serve as markers of increased lipid peroxidation due to oxygen free radical production exceeding antioxidant capacity |
| Inflammation | baseline, 3, 6, 9, 12 months | Serum levels of tumor necrosis factor-alpha (TNFα), soluble TNF receptors: sTNFR1 and sTNFR2 will be measured as markers of proinflammatory cytokine activity; interleukin-10 (IL-10) will be measured as a marker of anti-inflammatory cytokine activity |
Countries
United States
Outcome results
None listed